Ascendiant Capital maintains Buy on Atossa Therapeutics, reiterates $25 price target
Ascendiant Capital maintained its Buy rating on Atossa Therapeutics, keeping the price target at $25.00. This target suggests a potential upside of 1182.1% from the stock's previous close.